# SKYSCRAPER-02 (NCT04256421)

> A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04256421
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Small Cell Lung Cancer
- Interventions: Tiragolumab; Atezolizumab; Carboplatin; Etoposide; Placebo
- Enrollment: 490
- Primary outcome: Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)
- Primary outcome: Overall Survival (OS) in the PAS

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8
- Podcasts: 2
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=skyscraper-02-nct04256421

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04256421", "email": "<work email>"}; the inbox owner confirms by the emailed link.